6th Annual Future of Clinical Trials

Jacob Fleming Conferences26 - 27 October 2010, Vienna, Austria.
Leading Pharmaceutical players understand, how to complete trials with greater levels of cost-efficiency, timelines and success. Reveal, how to tailor clinical trials to the needs of the patients. Discuss the innovative methods of motivating patients and physicians. Learn from first hand experience, how to optimize patient recruitment & retention, and explore the patient pool in Russia and Southeastern Europe. Achieve the competitive advantage through increased partnering with academic centres of excellence, patient organizations and CROs.

Discuss with leading Pharma companies, what is the future of clinical trials & how to be prepared to succeed.

Key speakers:

  • Senior Vice President Global Clinical Operations, MerckSerono, Switzerland
  • Vice President Medical Affairs Global Diabetes Division, Sanofi Aventis, France
  • Deputy Head of Global Clinical Development Metabolism, Development Sub-Team Leader Dalcetrapib, Roche, Swizterland
  • VP R&D Science Policy, AstraZeneca, UK
  • Head Clinical Research, Novartis, Switzerland
  • Head Clinical Research, Novo Nordisk, Russia
  • Project Officer, VSOP, The Netherlands
  • Head of Biostatistics & Data Management, Global Clinical R&D, GSK Biologicals, Belgium
  • European AIDS Treatment Group (EATG), Germany
  • Chief Medical Officer Southern Europem, Novartis Vaccines & Diagnostics, Italy

Key topics:

  • New approaches to conducting clinical trials in a current dynamic and competitive environment
  • Examine key recruiting trends in Europe & Asia – exploit the patient pool and trials potential in the Southeastern Europe, Russia & Asian countries
  • Achieve competitive advantage through increased partnerships with academic centres of excellence, patient organizations & CROs
  • Gain first-hand information on PatientPartner project – how to establish partnership between stakeholders to the benefit of clinical trials and the treatment of patients in the future
  • Explore innovative methods of motivating investigators and patients
  • Understand the recent developments in the regulatory & legal environment
  • Best practices in designing a study protocol

Who should attend:
Vice Presidents, Heads, Directors, Senior Managers and Managers of: Clinical Development, Clinical Operations, Clinical Trials, Clinical Research, Patient Recruitment, Patient Retention, Site Management, Clinical Outsourcing, Sourcing Strategies, Medical Affairs, Contract Outsourcing, Clinical Strategy, Clinical Project Management, Regulatory Affairs, Clinical Research Associates, Clinical Research Organizations.

For further information and registration, please visit:
http://www.jacobfleming.com/jacob-fleming-group/conferences/life-science/6th-annual-future-of-clinical-trials?partner=worldpharmanews

About Jacob Fleming Group
Jacob Fleming Conferences are carefully designed to provide key strategic business information and the best networking opportunities for the participants. Our business to business conferences are highly interactive events with a limited number of delegates from specialized industry sectors. For each conference Jacob Fleming brings together selected senior level executives who become part of a premium community discussing the questions of the day and enjoying the value of a five star event.

Most Popular Now

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...

Roche announces the European Commission approval o…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the trea...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Discovery of anti-cancer chemistry makes skullcap …

The evolutionary secrets that enable the medicinal herb known as barbed skullcap to produce cancer fighting compounds have been unlocked by a collaboration of UK and Chin...

A soybean protein blocks LDL cholesterol productio…

A protein in soybeans blocks the production of a liver enzyme involved in the metabolism of triglycerides and low-density lipoprotein, scientists found in a recent study...